ReviewJTO clinical and research reports2022
Implementing Lung Cancer Screening in Europe: Taking a Systems Approach.
Review in JTO clinical and research reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Risk prediction for lung cancer screening: a systematic review and meta-regression.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Lung cancer screening with low-dose CT: definition of positive, indeterminate, and negative screen results. A nodule management recommendation from the European Society of Thoracic Imaging.European radiology · 2026Guideline
- Lung Cancer Screening With Low-Dose Computed Tomography.Deutsches Arzteblatt international · 2023Pooled it
- Late-Stage Presentation and Diagnostic Gaps in Romanian Lung Cancer Patients: A Retrospective Tertiary Center Analysis with Implications for Scalable Screening.Diagnostics (Basel, Switzerland) · 2026Article
- Commercial AI for CT lung cancer screening: product capabilities, coverage of nodule management tasks and supporting evidence.European radiology · 2026Article
- Recruitment strategies and outcomes in lung cancer screening programmes: a scoping review.European radiology · 2026Article
- Socioeconomic Disparities in Lung Cancer Screening Participation.JAMA network open · 2026Article
- AI-accelerated 3D gradient echo versus ultrashort echo time MRI for lung nodule detection and measurement.Radiology advances · 2026Article
- Blood-based DNA methylation marker model for short-term and long-term lung cancer risk prediction.BMC medicine · 2026Article
- Beyond the Scan: Adapting Multimodal Lung Cancer Screening for Central and Eastern Europe-Overcoming Systemic Barriers and Epidemiological Confounders.Medical sciences (Basel, Switzerland) · 2026Review
- Progressive pulmonary fibrosis.European radiology · 2026Review
- The landscape of lung cancer screening globally: a comparison of established programs and estimates of eligibility to participate.The Lancet regional health. Western Pacific · 2026Review
- Strategies for sustainable lung cancer screening: a multi-faceted perspective to long-term surveillance in SOLACE.Insights into imaging · 2026Article
- Patient and Healthcare Provider Barriers in the LDCT Lung Cancer Screening Continuum.Diagnostics (Basel, Switzerland) · 2026Review
- Artificial intelligence as an independent reader of risk-dominant lung nodules: influence of CT reconstruction parameters.European radiology · 2026Article
- Independent Predictors Associated with Patient Refusal of Invasive Diagnostic Procedures After Positive LDCT Lung Cancer Screening.Diagnostics (Basel, Switzerland) · 2026Article
- Review
- Awareness of lung cancer screening among smokers: a Lebanese experience.Frontiers in oncology · 2026Article
- Eligibility for Lung Cancer Screening in Switzerland: A Comparative Analysis of Three Data Sources From Lausanne and the Canton of Vaud.International journal of public health · 2026Article
- European Code Against Cancer, 5th edition - organised cancer screening programmes.Molecular oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 10 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the leading cause of cancer death in Europe. Screening by means of low-dose computed tomography (LDCT) can shift detection to an earlier stage and reduce lung cancer mortality in high-risk individuals. However, to date, Poland, Croatia, Italy, and Romania are the only European countries to commit to large-scale implementation of targeted LDCT screening. Using a health systems approach, this article evaluates key factors needed to enable the successful implementation of screening programs across Europe. Recent literature on LDCT screening was reviewed for 10 countries (Belgium, Croatia, France, Germany, Italy, the Netherlands, Poland, Spain, Sweden, and United Kingdom) and complemented by 17 semistructured interviews with local experts. Research findings were mapped against a health systems framework adapted for lung cancer screening. The European policy landscape is highly variable, but potential barriers to implementation are similar across countries and consistent with those reported for other cancer screening programs. While consistent quality and safety of screening must be ensured across all screening centers, system factors are also important. These include appropriate data infrastructure, targeted recruitment methods that ensure equity in participation, sufficient capacity and workforce training, full integration of screening with multidisciplinary care pathways, and smoking cessation programs. Stigma and underlying perceptions of lung cancer as a self-inflicted condition are also important considerations. Building on decades of implementation research, governments now have a unique opportunity to establish effective, efficient, and equitable lung cancer screening programs adapted to their health systems, curbing the impact of lung cancer on their populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.